newsfilter
← Latest News
Business Wire·

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results

Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023 Continued Progress on Second Program for Hearing Restoration, F